LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32
Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025
Express News | Astria Therapeutics Inc - Navenibart Shows Favorable Safety and Well-Tolerated Profile
Astria Therapeutics Announces Positive Final Results From Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
Express News | Astria Therapeutics Announces Positive Final Results From Target Enrollment in the Alpha-Star Phase 1B/2 Trial of Navenibart for Hae
Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310, A Monoclonal Antibody OX40 Antagonist For The Treatment Of Atopic Dermatitis
Express News | Astria Therapeutics Inc: Phase 1a Trial of Star-0310 in Healthy Volunteers Expected to Initiate in Q1 2025
Express News | Astria Therapeutics Announces FDA Clearance of Ind Application for Star-0310, a Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
Astria Therapeutics (NASDAQ:ATXS) Is In A Good Position To Deliver On Growth Plans
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $23 to $35
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Astria Therapeutics Analyst Ratings
Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $28 From $26
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
Express News | Astria Therapeutics Q3 EPS $(0.42) Misses $(0.41) Estimate
Astria Expects Cash, Cash Equivalents and Short-Term Investments as of Sept 30 Sufficient to Fund Ops Into Mid-2027 >ATXS
No Data